Charles Schwab
NXTC icon

Charles Schwab’s NextCure NXTC Stock Holding History

Charles Schwab’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-833
Closed -$13.7K – 3508
2024
Q3 		$13.7K Hold
833
– – ﹤0.01% 3498
2024
Q2 		$15.9K Hold
833
– – ﹤0.01% 3599
2024
Q1 		$22.3K Hold
833
– – ﹤0.01% 3429
2023
Q4 		$11.4K Hold
833
– – ﹤0.01% 3518
2023
Q3 		$12.9K Hold
833
– – ﹤0.01% 3547
2023
Q2 		$18K Hold
833
– – ﹤0.01% 3572
2023
Q1 		$14.8K Hold
833
– – ﹤0.01% 3529
2022
Q4 		$14.1K Hold
833
– – ﹤0.01% 3522
2022
Q3 		$28K Hold
833
– – ﹤0.01% 3447
2022
Q2 		$47K Hold
833
– – ﹤0.01% 3400
2022
Q1 		$49K Hold
833
– – ﹤0.01% 3527
2021
Q4 		$60K Buy
+833
New +$69.7K ﹤0.01% 3496
2021
Q3 		– Sell
-5,073
Closed -$489K – 3535
2021
Q2 		$489K Sell
5,073
-3,101
-38% -$317K ﹤0.01% 3173
2021
Q1 		$982K Buy
8,174
+183
+2% +$26.5K ﹤0.01% 2867
2020
Q4 		$1.05M Buy
7,991
+604
+8% +$78K ﹤0.01% 2757
2020
Q3 		$781K Buy
7,387
+918
+14% +$113K ﹤0.01% 2732
2020
Q2 		$1.67M Buy
6,469
+695
+12% +$265K ﹤0.01% 2474
2020
Q1 		$2.57M Buy
5,774
+132
+2% +$70.5K ﹤0.01% 2169
2019
Q4 		$3.81M Buy
5,642
+3,322
+143% +$1.67M ﹤0.01% 2166
2019
Q3 		$859K Buy
2,320
+174
+8% +$56.6K ﹤0.01% 2614
2019
Q2 		$386K Buy
+2,146
New +$446K ﹤0.01% 2932

Other funds holding NXTC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's NXTC Position: Q4 2024 in Review

Charles Schwab sold out of NextCure (NXTC) in Q4 2024, closing a stake of 833 shares — an estimated $13.7K sold.

Charles Schwab first reported a position in NXTC in Q2 2019 and held it in 21 quarters. The position peaked at $3.81M in Q4 2019. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2024.

  • Charles Schwab reported no remaining NextCure position as of Q4 2024 after selling out during the quarter.
  • Charles Schwab sold 833 NextCure shares in Q4 2024, an estimated $13.7K.
  • Charles Schwab first reported a position in NextCure in Q2 2019 and held it in 21 quarters.
  • Charles Schwab's NextCure position peaked at $3.81M in Q4 2019.
  • 45 funds tracked by Wall St. Rank held NextCure as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.